BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37259819)

  • 1. Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case-control study.
    Si X; Zheng X; Tian X; Wang H; Xu Y; Zhao J; Chen M; Zhong W; Wang M; Zhang L; Zhang X
    Thorac Cancer; 2023 Jul; 14(21):2038-2044. PubMed ID: 37259819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.
    Kowalski B; Valaperti A; Bezel P; Steiner UC; Scholtze D; Wieser S; Vonow-Eisenring M; Widmer A; Kohler M; Franzen D
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1711-1720. PubMed ID: 34347128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis.
    Yu W; He Y; Shang Y; Guo T; Wang K; Liang H; Xue J; Ma X; Mu X; Li R; Gao Z
    Clin Immunol; 2023 Feb; 247():109230. PubMed ID: 36646189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
    Suresh K; Naidoo J; Zhong Q; Xiong Y; Mammen J; de Flores MV; Cappelli L; Balaji A; Palmer T; Forde PM; Anagnostou V; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Lin CT; Feller-Kopman D; Lerner AD; Lee H; Shafiq M; Yarmus L; Lipson EJ; Soloski M; Brahmer JR; Danoff SK; D'Alessio F
    J Clin Invest; 2019 Jul; 129(10):4305-4315. PubMed ID: 31310589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
    Franken A; Van Mol P; Vanmassenhove S; Donders E; Schepers R; Van Brussel T; Dooms C; Yserbyt J; De Crem N; Testelmans D; De Wever W; Nackaerts K; Vansteenkiste J; Vos R; Humblet-Baron S; Lambrechts D; Wauters E
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Deep lung--cellular reaction to HIV].
    Tavares Marques MA; Alves V; Duque V; Botelho MF
    Rev Port Pneumol; 2007; 13(2):175-212. PubMed ID: 17492233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma.
    Strippoli S; Fucci L; Negri A; Putignano D; Cisternino ML; Napoli G; Filannino R; De Risi I; Sciacovelli AM; Guida M
    J Transl Med; 2020 Dec; 18(1):473. PubMed ID: 33302981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Wang YN; Lou DF; Li DY; Jiang W; Dong JY; Gao W; Chen HC
    Oncol Lett; 2020 Jul; 20(1):611-622. PubMed ID: 32565986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis.
    Bezel P; Valaperti A; Steiner U; Scholtze D; Wieser S; Vonow-Eisenring M; Widmer A; Kowalski B; Kohler M; Franzen DP
    Cancer Immunol Immunother; 2021 Jul; 70(7):1867-1876. PubMed ID: 33394095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
    Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
    Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis.
    Wang PM; Zhang ZW; Zhang S; Xing Q; Zhao ZY; Lin QH; Shen LH; Xia ZL; Li FF; Zhu B
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):8019-8026. PubMed ID: 36944820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases.
    Suga M; Iyonaga K; Ichiyasu H; Saita N; Yamasaki H; Ando M
    Eur Respir J; 1999 Aug; 14(2):376-82. PubMed ID: 10515417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.
    Kim ST; Sheshadri A; Shannon V; Kontoyiannis DP; Kantarjian H; Garcia-Manero G; Ravandi F; Im JS; Boddu P; Bashoura L; Balachandran DD; Evans SE; Faiz S; Ruiz Vazquez W; Divenko M; Mathur R; Tippen SP; Gumbs C; Neelapu SS; Naing A; Wang L; Diab A; Futreal A; Nurieva R; Daver N
    Front Immunol; 2020; 11():590494. PubMed ID: 33552049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
    Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
    Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
    Chao Y; Zhou J; Hsu S; Ding N; Li J; Zhang Y; Xu X; Tang X; Wei T; Zhu Z; Chu Q; Neal JW; Wu JT; Song Y; Hu J
    Transl Lung Cancer Res; 2022 Feb; 11(2):295-306. PubMed ID: 35280322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients.
    Küpeli E; Karnak D; Beder S; Kayacan O; Tutkak H
    Respiration; 2008; 75(1):73-8. PubMed ID: 17975298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases.
    Vasakova M; Sterclova M; Kolesar L; Slavcev A; Pohunek P; Sulc J; Skibova J; Striz I
    Scand J Immunol; 2009 Mar; 69(3):268-74. PubMed ID: 19281539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
    Suzuki K; Yanagihara T; Matsumoto K; Kusaba H; Yamauchi T; Ikematsu Y; Tanaka K; Otsubo K; Inoue H; Yoneshima Y; Iwama E; Arimura-Omori M; Harada E; Hamada N; Okamoto I; Nakanishi Y
    Int Immunol; 2020 Jul; 32(8):547-557. PubMed ID: 32253426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.